Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Adam Sperling

Has grant

Assistant Professor

Stanford University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Recent Grants

Grant: Close

Defining mechanisms of thalidomide analog resistance

Open Date: 2020-07-01

Close Date: 2025-06-30

Grant: Close

[title missing from source]

Open Date: 2000-05-15

Close Date: 2001-08-15

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (10)

Emily Durlacher

Dana-Farber Cancer Institute

UNITED STATES

View details

Hadi Nia

Member

Boston University

UNITED STATES

View details

Jill Corre

FRANCE

View details

Christian Sebastian Michel

Attending physician, Head of Myeloma Service

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY

View details

sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

UNITED STATES

View details

Rahul Banerjee

Assistant Professor

Fred Hutch Cancer Center

UNITED STATES

View details

Benjamin Derman

Assistant Professor

University of Chicago

UNITED STATES

View details

Andrzej J. Jakubowiak

Professor of Medicine

University of Chicago

UNITED STATES

View details

S. Vincent Rajkumar

Professor of Medicine

Mayo Clinic Minnesota

UNITED STATES

View details

Markus Hansson

Professor

Sahlgrenska universitetssjukhuset

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adam Sperling

Research Interests

Explore related searches

Recent Grants

Articles (20)

Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma

Crossing the Threshold to Cure in Multiple Myeloma

Clinical Impact and Dynamics of Clonal Hematopoiesis with <sup>177</sup>Lu-PSMA-617 Therapy in Advanced Prostate Cancer.

Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists.

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.

Two clones, one niche: how CH shapes the MM microenvironment.

Collaborators (10)

Emily Durlacher

Hadi Nia

Jill Corre

Christian Sebastian Michel

sandra susanibar adaniya

Rahul Banerjee

Benjamin Derman

Andrzej J. Jakubowiak

S. Vincent Rajkumar

Markus Hansson

Make your next move.

Adam Sperling

Research Interests

Explore related searches

Recent Grants

Articles (20)

Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma

Crossing the Threshold to Cure in Multiple Myeloma

Clinical Impact and Dynamics of Clonal Hematopoiesis with &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 Therapy in Advanced Prostate Cancer.

Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists.

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.

Two clones, one niche: how CH shapes the MM microenvironment.

Collaborators (10)

Emily Durlacher

Hadi Nia

Jill Corre

Christian Sebastian Michel

sandra susanibar adaniya

Rahul Banerjee

Benjamin Derman

Andrzej J. Jakubowiak

S. Vincent Rajkumar

Markus Hansson

Make your next move.

Clinical Impact and Dynamics of Clonal Hematopoiesis with <sup>177</sup>Lu-PSMA-617 Therapy in Advanced Prostate Cancer.